| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
In this research, we tried to elucidate the mechanism of drug-induced liver injury (DILI) onset in humans in order to improve the predictability of DILI risk at the development stage of pharmaceuticals.
In many drugs which have high risk for fulminant hepatitis (eg, benzbromarone (BBR)), mitochondrial permeability transition (MPT) due to the production of highly toxic metabolites in the liver was observed. Moreover, in mice lacking cyclophilin D which controls MPT pore opening, BBR induced DILI was successfully suppressed. In addition, we succeeded in constructing a system that can conveniently evaluate the toxic potential in mitochondria of metabolites. These results are expected to contribute to the production of safe medicines.
|
